Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Basking Biosciences.

    Client Virtual Booth

    BASKING BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Basking Biosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1275 Kinnear Road Columbus OH 43212
    Telephone
    Telephone
    919-345-7933
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.baskingbiosciences.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

    Details:

    Basking will utilize the proceeds to accelerate clinical development of BB-031 (originally named DTRI-031), a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), being evaluated for the treatment of acute ischemic stroke.


    Lead Product(s): BB-031

    Therapeutic Area: Neurology Product Name: BB-031

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Longview Ventures

    Deal Size: $55.0 million Upfront Cash: Undisclosed

    Deal Type: Financing February 01, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023

    Details:

    BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process. It is being developed for acute ischemic stroke.


    Lead Product(s): BB-031

    Therapeutic Area: Neurology Product Name: BB-031

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conferen...

    Details:

    BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF), a key component and driver of blood clot formation, propagation and stabilization.


    Lead Product(s): BB-031

    Therapeutic Area: Neurology Product Name: BB-031

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 31, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basking Biosciences, Inc. Completes $5.4M Seed Financing

    Details:

    The Company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031.


    Lead Product(s): DTRI-031

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: DTRI-031

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Rev1 Ventures

    Deal Size: $5.4 million Upfront Cash: Undisclosed

    Deal Type: Financing December 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search